The success of yourpivotal hematology study will depend on partnering with the right CRO. One of our hematology clients recently shared the five metrics they look for in a CRO partner.
1. Does the CRO have experience in diverse hematology indications?
This client had a promising portfolio in a number of indications and wanted to be sure their partner could handle a wide range of patient groups; this is important as they do not yet know which groups will respond best to their treatments. PSI has experience in49 bleeding disorder protocols across different age groups and design complexities, including hemophilia, Von Willebrand disease, Glanzmann thrombasthenia, and congenital factor VII deficiency experience; and 60 rare hematology disorder studies, including indications such as anemia, Thrombotic Microangiopathy (TMA), Paroxysmal nocturnal hemoglobinuria (PNH), and Thrombocytopenic Purpura (TTP).
2. Does the CRO have access to hematology sites?
Given the breadth of the portfolio and the rare populations, our sponsor wanted to be sure they’d have plenty of options for site selection.They were able to consider ournetwork of over 2,000 hematology sites in 56 countries that are highly interested in exploring new treatment options for their patients. In many of these groups, there is still a lot of unmet need, and patients are keen to try new treatments.
3. Do these sites deliver quality data?
Protocol deviations are expensive and can harm your chances of approval. Our top recruiting hematology sites passed24 FDA/4 EMA inspections with no major observations.
4. Has the CRO delivered any drug approvals?
Ultimately, we all want the drug to reach patients. PSI has contributed pivotal data in8 recent FDA and/or EMA drug approvals in rare blood disorders.
5. And, importantly, does the CRO deliver?
Living in an uncertain world, there are no guarantees.You’ll need a partner who can share a strong track record of fast problem–solving, allowing you to navigate any hurdles quickly. At PSI, more than 90% of clinical trials run on time.
Are you planning a hematology study for 2025? Let’s meet and discuss what’s on your checklist. The sooner we do it, the better prepared your study will be.
5 Questions to Ask When Choosing a Hematology CRO
The success of your pivotal hematology study will depend on partnering with the right CRO. One of our hematology clients recently shared the five metrics they look for in a CRO partner.
1. Does the CRO have experience in diverse hematology indications?
This client had a promising portfolio in a number of indications and wanted to be sure their partner could handle a wide range of patient groups; this is important as they do not yet know which groups will respond best to their treatments. PSI has experience in 49 bleeding disorder protocols across different age groups and design complexities, including hemophilia, Von Willebrand disease, Glanzmann thrombasthenia, and congenital factor VII deficiency experience; and 60 rare hematology disorder studies, including indications such as anemia, Thrombotic Microangiopathy (TMA), Paroxysmal nocturnal hemoglobinuria (PNH), and Thrombocytopenic Purpura (TTP).
2. Does the CRO have access to hematology sites?
Given the breadth of the portfolio and the rare populations, our sponsor wanted to be sure they’d have plenty of options for site selection. They were able to consider our network of over 2,000 hematology sites in 56 countries that are highly interested in exploring new treatment options for their patients. In many of these groups, there is still a lot of unmet need, and patients are keen to try new treatments.
3. Do these sites deliver quality data?
Protocol deviations are expensive and can harm your chances of approval. Our top recruiting hematology sites passed 24 FDA/4 EMA inspections with no major observations.
4. Has the CRO delivered any drug approvals?
Ultimately, we all want the drug to reach patients. PSI has contributed pivotal data in 8 recent FDA and/or EMA drug approvals in rare blood disorders.
5. And, importantly, does the CRO deliver?
Living in an uncertain world, there are no guarantees. You’ll need a partner who can share a strong track record of fast problem–solving, allowing you to navigate any hurdles quickly. At PSI, more than 90% of clinical trials run on time.
Are you planning a hematology study for 2025? Let’s meet and discuss what’s on your checklist. The sooner we do it, the better prepared your study will be.
Share